Items Tagged ‘fulvestrant’

October 5, 2017

FDA approves new treatment for certain advanced or metastatic breast cancers


The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine […]

View full entry

Tags: abemaciclib, Breast Cancer, fulvestrant, hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Metastatic Breast Cancer, News, Precision Cancer Medicine, Verzenio